Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors
Randomized Controlled Trial Comparing Single-dose and Divided-dose G-CSF for Peripheral Blood Stem Cell Mobilization in Healthy Donors for Allogeneic Hematopoietic Stem Cell Transplantation.
National and international guidelines/consensus recommend G-CSF (granulocyte colony-stimulating factor) at 10 μg/kg/day as a single daily dose or divided into two daily doses for mobilization in healthy donors for allogeneic hematopoietic stem cell transplantation. However, there is no consensus or standard regarding single versus divided dosing, and high-quality evidence is lacking. Existing randomized controlled trials have small sample sizes and inconsistent conclusions, and none have focused on Asian population characteristics (e.g., body weight and drug metabolism differences). This study aims to provide level I evidence to optimize donor experience and define the optimal administration strategy.
Inclusion criteria: Healthy allogeneic stem cell donors aged 18-60 years, meeting institutional standard donor screening criteria (HLA matching, normal blood counts, normal liver and kidney function, negative infection screening), and providing written informed consent.
Primary endpoint: The rate of achieving a first apheresis yield of ≥ 4 × 10⁶ CD34⁺ cells/kg (donor body weight) after 5 days of G-CSF mobilization.
Secondary endpoints: The rate of achieving ≥ 2 × 10⁶ CD34⁺ cells/kg with at most one apheresis; time to myeloid, platelet, and erythroid engraftment in recipients; the proportion and composition of immune cells (CD34⁺, CD3⁺, CD19⁺, CD56⁺, etc.) in the apheresis product; donor adverse events; donor-reported outcomes; and the difference in CD34⁺ stem cell yields between single-dose and divided-dose mobilization.
Intervention: G-CSF will be administered at a total dose of 10 μg/kg/day, either as a single daily injection or divided into two equal daily injections.
This study is designed to investigate whether single-dose or divided-dose G-CSF administration is superior for mobilizing healthy donors in allogeneic hematopoietic stem cell transplantation.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
National and international guidelines/consensus recommend G-CSF (granulocyte colony-stimulating factor) at 10 μg/kg/day as a single daily dose or divided into two daily doses for mobilization in healthy donors for allogeneic hematopoietic stem cell transplantation. However, there is no consensus or standard regarding single versus divided dosing, and high-quality evidence is lacking. Existing randomized controlled trials have small sample sizes and inconsistent conclusions, and none have focused on Asian population characteristics (e.g., body weight and drug metabolism differences). This study aims to provide level I evidence to optimize donor experience and define the optimal administration strategy.
Inclusion criteria: Healthy allogeneic stem cell donors aged 18-60 years, meeting institutional standard donor screening criteria (HLA matching, normal blood counts, normal liver and kidney function, negative infection screening), and providing written informed consent.
Primary endpoint: The rate of achieving a first apheresis yield of ≥ 4 × 10⁶ CD34⁺ cells/kg (donor body weight) after 5 days of G-CSF mobilization.
Secondary endpoints: The rate of achieving ≥ 2 × 10⁶ CD34⁺ cells/kg with at most one apheresis; time to myeloid, platelet, and erythroid engraftment in recipients; the proportion and composition of immune cells (CD34⁺, CD3⁺, CD19⁺, CD56⁺, etc.) in the apheresis product; donor adverse events; donor-reported outcomes; and the difference in CD34⁺ stem cell yields between single-dose and divided-dose mobilization.
Intervention: G-CSF will be administered at a total dose of 10 μg/kg/day, either as a single daily injection or divided into two equal daily injections.
Weight-based mobilization: G-CSF 10 μg/kg/day × 5 days, SC, once daily or in two divided doses (max 7 days). Apheresis begins on day 5; subsequent dosing and collections are guided by the CD34⁺ yield, not to exceed 7 days.
This study is designed to investigate whether single-dose or divided-dose G-CSF administration is superior for mobilizing healthy donors in allogeneic hematopoietic stem cell transplantation.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: YIBO WU
- Telefoonnummer: +8657187233801
- E-mail: wuyibo7@126.com
Studie Locaties
-
-
Hunan
-
Changsha, Hunan, China
- Werving
- Xiangya Hospital of Central South University
-
Contact:
- Yajing Xu
- Telefoonnummer: +8657187233801
- E-mail: xyyajingxu@csu.edu.cn
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Werving
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Contact:
- Yang Xu
- Telefoonnummer: +8657187233801
- E-mail: yxu@zju.edu.cn
-
Hangzhou, Zhejiang, China
- Werving
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
-
Contact:
- Haowen Xiao
- Telefoonnummer: +8657187233801
- E-mail: haowenxiaoxiao@zju.edu.cn
-
Hangzhou, Zhejiang, China
- Werving
- The First Affiliated Hospital, Zhejiang University School of Medicine.
-
Contact:
- YIBO WU
- Telefoonnummer: +8657187233801
- E-mail: wuyibo7@126.com
-
Jinhua, Zhejiang, China
- Werving
- Jinhua Central Hospital
-
Contact:
- Lihong Ni
- Telefoonnummer: +8657187233801
- E-mail: nilihongwy@163.com
-
Ningbo, Zhejiang, China
- Werving
- The First Affiliated Hospital of Ningbo University
-
Contact:
- Lieguang Chen
- Telefoonnummer: +8657187233801
- E-mail: fyychenlieguang@nbu.edu.cn
-
Ningbo, Zhejiang, China
- Werving
- The affiliated people's hospital of ningbo university
-
Contact:
- Ying Lu
- Telefoonnummer: +8657187233801
- E-mail: rmluying@nbu.edu.cn
-
Wenzhou, Zhejiang, China
- Werving
- The First Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Yi Chen
- Telefoonnummer: +8657187233801
- E-mail: chenyi19527@163.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Age 18-65 years.
- Provision of written informed consent.
- White blood cell (WBC) count > 2.5 × 10⁹/L.
- Absolute neutrophil count (ANC) > 1.5 × 10⁹/L and platelet count > 100 × 10⁹/L.
- Deemed suitable as a donor by the investigator based on donor physical examination and HLA matching.
- Body weight ≥ 40 kg for females and ≥ 45 kg for males.
Exclusion Criteria:
- Currently having any disease or condition that, in the judgment of the investigator, would make the donor unsuitable for participation in this study, such as severe neurological, hepatic, renal, endocrine, cardiovascular, hematologic, gastrointestinal, respiratory, or metabolic diseases; malignancies; myeloproliferative disorders; or psychiatric illnesses.
- Currently having an active infection requiring systemic therapy.
- Allergy to the study drug.
- Presence of a malignant tumor.
- Untreated HBV infection with HBV-DNA above the lower limit of detection.
- HIV infection.
- Addition of any new medication within 2 weeks prior to entry into this study.
- Female donors who are pregnant or breastfeeding.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Divided-dose Arm
G-CSF 10 μg/kg per day divided into two equal subcutaneous doses daily for 5 days (up to 7 days if needed).
|
G-CSF 10 μg/kg per day divided into two equal subcutaneous doses daily for 5 days (up to 7 days if needed)
|
|
Actieve vergelijker: Single-dose Arm
G-CSF 10 μg/kg administered subcutaneously once daily for 5 days (up to 7 days if needed based on CD34⁺ yield).
|
G-CSF 10 μg/kg administered subcutaneously once daily for 5 days (up to 7 days if needed based on CD34⁺ yield).
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of donors achieving a first apheresis yield of ≥ 4 × 10⁶ CD34⁺ cells/kg (donor weight).
Tijdsspanne: From enrollment to the end of stem cell collection (8 weeks)
|
Proportion of donors achieving a first apheresis yield of ≥ 4 × 10⁶ CD34⁺ cells/kg (donor weight).
|
From enrollment to the end of stem cell collection (8 weeks)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of donors achieving a yield of ≥ 2 × 10⁶ CD34⁺ cells/kg (donor weight) with no more than one apheresis.
Tijdsspanne: From enrollment to the end of stem cell collection (8 weeks)
|
Proportion of donors achieving a yield of ≥ 2 × 10⁶ CD34⁺ cells/kg (donor weight) with no more than one apheresis.
|
From enrollment to the end of stem cell collection (8 weeks)
|
|
Cumulative incidence rates of neutrophil engraftment in allogeneic stem cell transplant recipients.
Tijdsspanne: 28 days after transplantation
|
Defined as time from stem cell infusion to the first of three consecutive days with ANC ≥ 0.5 × 10⁹/L.
|
28 days after transplantation
|
|
Cumulative incidence rates of platelet engraftment in allogeneic stem cell transplant recipients.
Tijdsspanne: 28 days after transplantation
|
Proportion of recipients achieving platelet count ≥ 20 × 10⁹/L with no platelet transfusion for at least 7 consecutive days, by Day +28 post-transplant.
|
28 days after transplantation
|
|
Cumulative incidence rates of erythroid engraftment in allogeneic stem cell transplant recipients.
Tijdsspanne: 28 days after transplantation
|
Proportion of recipients achieving hemoglobin ≥ 60 g/L without red blood cell transfusion for at least 7 consecutive days, by Day +28 post-transplant.
|
28 days after transplantation
|
|
The proportion and composition of immune cells (including CD34⁺, CD3⁺, CD19⁺, CD56⁺, etc.) in the apheresis product
Tijdsspanne: From enrollment to the end of stem cell collection (8 weeks)
|
The proportion and composition of immune cells (including CD34⁺, CD3⁺, CD19⁺, CD56⁺, etc.) in the apheresis product
|
From enrollment to the end of stem cell collection (8 weeks)
|
|
Donor adverse events and recipient-reported outcomes
Tijdsspanne: From enrollment to the end of stem cell collection (8 weeks)
|
Donor adverse events and recipient-reported outcomes
|
From enrollment to the end of stem cell collection (8 weeks)
|
|
Comparison of peripheral blood CD34⁺ cell counts (cells/μL) on Days 1, 2, 3, 4, and 5 between healthy donors mobilized with single-dose versus divided-dose G-CSF
Tijdsspanne: From enrollment to the end of stem cell collection (8 weeks)
|
Comparison of peripheral blood CD34⁺ cell counts (cells/μL) on Days 1, 2, 3, 4, and 5 between healthy donors mobilized with single-dose versus divided-dose G-CSF
|
From enrollment to the end of stem cell collection (8 weeks)
|
|
Comparison of the rate of engraftment failure in recipients between the two groups
Tijdsspanne: From enrollment to the end of stem cell collection (8 weeks)
|
Comparison of the rate of engraftment failure in recipients between the two groups
|
From enrollment to the end of stem cell collection (8 weeks)
|
|
Comparison of overall survival (OS) rates at 2 years in recipients between the two groups;
Tijdsspanne: 2 years post transplantation
|
Comparison of overall survival (OS) rates at 2 years in recipients between the two groups;
|
2 years post transplantation
|
|
Comparison of overall survival (OS) rates at 5 years in recipients between the two groups;
Tijdsspanne: 5 years post transplantation
|
Comparison of overall survival (OS) rates at 5 years in recipients between the two groups;
|
5 years post transplantation
|
|
Comparison of CD34⁺ stem cell yield in the apheresis product between the two groups
Tijdsspanne: From enrollment to the end of stem cell collection (8 weeks)
|
Comparison of CD34⁺ stem cell yield in the apheresis product between the two groups
|
From enrollment to the end of stem cell collection (8 weeks)
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: YI LUO, Zhejiang University
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ZJU-GCSF
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .